首页> 美国卫生研究院文献>American Journal of Physiology - Heart and Circulatory Physiology >An acute rise in intraluminal pressure shifts the mediator of flow-mediated dilation from nitric oxide to hydrogen peroxide in human arterioles
【2h】

An acute rise in intraluminal pressure shifts the mediator of flow-mediated dilation from nitric oxide to hydrogen peroxide in human arterioles

机译:管腔内压力的急剧上升将人小动脉中的流介导的扩张介质从一氧化氮转变为过氧化氢

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Endothelial nitric oxide (NO) is the primary mediator of flow-mediated dilation (FMD) in human adipose microvessels. Impaired NO-mediated vasodilation occurs after acute and chronic hypertension, possibly due to excess generation of reactive oxygen species (ROS). The direct role of pressure elevation in this impairment of human arteriolar dilation is not known. We tested the hypothesis that elevation in pressure is sufficient to impair FMD. Arterioles were isolated from human adipose tissue and cannulated, and vasodilation to graded flow gradients was measured before and after exposure to increased intraluminal pressure (IILP; 150 mmHg, 30 min). The mediator of FMD was determined using pharmacological agents to reduce NO [NG-nitro-l-arginine methyl ester (l-NAME), 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO)], or H2O2 [polyethylene glycol (PEG)-catalase], and mitochondrial (mt) ROS was quantified using fluorescence microscopy. Exposure to IILP decreased overall FMD (max %dilation: 82.7 ± 4.9 vs. 62 ± 5.6; P < 0.05). This dilation was abolished by treatment with l-NAME prepressure and PEG-catalase after IILP (max %dilation: l-NAME: 23.8 ± 6.1 vs. 74.8 ± 8.6; PEG-catalase: 71.8 ± 5.9 vs. 24.6 ± 10.6). To examine if this change was mediated by mtROS, FMD responses were measured in the presence of the complex I inhibitor rotenone or the mitochondrial antioxidant mitoTempol. Before IILP, FMD was unaffected by either compound; however, both inhibited dilation after IILP. The fluorescence intensity of mitochondria peroxy yellow 1 (MitoPY1), a mitochondria-specific fluorescent probe for H2O2, increased during flow after IILP (%change from static: 12.3 ± 14.5 vs. 127.9 ± 57.7). These results demonstrate a novel compensatory dilator mechanism in humans that is triggered by IILP, inducing a change in the mediator of FMD from NO to mitochondria-derived H2O2.
机译:内皮型一氧化氮(NO)是人类脂肪微血管中血流介导的扩张(FMD)的主要介质。在急性和慢性高血压后,受损的NO介导的血管舒张发生,可能是由于活性氧(ROS)的过量产生。尚不清楚压力升高在人小动脉扩张这种损害中的直接作用。我们检验了压力升高足以损害口蹄疫的假设。从人体脂肪组织中分离出小动脉并进行插管,并在暴露于升高的腔内压力(IILP; 150 mmHg,30分钟)之前和之后测量血管扩张至渐变的血流梯度。使用药理学方法确定FMD的介体,以还原NO [N G -硝基-1-精氨酸甲酯(1-NAME),2-(4-羧苯基)-4、4、5,使用荧光显微镜对5-四甲基咪唑啉-1-氧基1-3氧化物(c-PTIO)或H2O2 [聚乙二醇(PEG)-过氧化氢酶]和线粒体(mt)ROS进行定量。暴露于IILP会降低总体FMD(最大扩张百分比:82.7±4.9与62±5.6; P <0.05)。通过IILP后用l-NAME预压和PEG-过氧化氢酶处理消除了这种扩张(最大%扩张:l-NAME:23.8±6.1对74.8±8.6; PEG-过氧化氢酶:71.8±5.9对24.6±10.6)。为了检查这种变化是否是由mtROS介导的,在复合物I抑制剂鱼藤酮或线粒体抗氧化剂mitoTempol的存在下测量FMD反应。在进行IILP之前,FMD不受任何一种化合物的影响。然而,两者均抑制了IILP后的扩张。线粒体过氧黄1(MitoPY1)的荧光强度是针对H2O2的线粒体特异性荧光探针,在IILP流动期间会增加(相对于静态的百分数变化:12.3±14.5对127.9±57.7)。这些结果证明了IILP触发的人类新的补偿性扩张器机制,导致FMD介体从NO转变为线粒体H2O2。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号